The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Brief Title: Phase II Study of Neoadjuvant Weekly Paclitaxel and Carboplatin Followed by Dose Dense Epirubicin and Cyclophosphamide in Stage II and III Triple Negative Breast Cancer
Official Title: A Prospective, Belgian Multi-center, Single-arm, Phase II Study of Neoadjuvant Weekly Paclitaxel and Carboplatin Followed by Dose Dense Epirubicin and Cyclophosphamide in Stage II and III Triple Negative Breast Cancer
Study ID: NCT04224922
Brief Summary: This is a prospective Belgian, multi-center, open-label, single-arm phase II study of weekly paclitaxel at a dose of 80mg/m² in combination with weekly carboplatin (AUC=2), for 12 weeks, followed by 4 cycles of dose dense epirubicin at a dose of 90 mg/m² and cyclophosphamide at a dose of 600 mg/m² every 2 weeks (plus Long acting GCSF at day 2) administrated preoperatively in locally advanced operable stage II and III triple negative breast cancer to evaluate tumor response in the breast and the axilla.
Detailed Description:
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: FEMALE
Healthy Volunteers: No
Onze Lieve Vrouw Ziekenhuis, Aalst, , Belgium
Cliniques Sud Luxembourg, Arlon, , Belgium
Imelda Ziekenhuis, Bonheiden, , Belgium
AZ klina, Brasschaat, , Belgium
St Lucas, Brugge, , Belgium
Institut Jules Bordet, Brussels, , Belgium
Universitaire Ziekenhuis Antwerpen, Edegem, , Belgium
AZ Maria Middelares, Gent, , Belgium
AZ St Lucas, Gent, , Belgium
AZ Groeninge, Kortrijk, , Belgium
UZ Leuven, Leuven, , Belgium
CHR Citadelle, Liège, , Belgium
CHU Sart-Tilman, Liège, , Belgium
CMSE, Namur, , Belgium
Clinique st Pierre, Ottignies, , Belgium
CHWAPI, Tournai, , Belgium
CHR Verviers, Verviers, , Belgium
CHU Mont-Godinne, Yvoir, , Belgium
Name: Christel Fontaine, Dr.
Affiliation: Universitair Ziekenhuis Brussel
Role: PRINCIPAL_INVESTIGATOR